Mode
Text Size
Log in / Sign up
Early Phase 1 N=12 Randomized Triple-blind Basic Science

Ivermectin and Human Immunity

Ivermectin

Enrolled (actual)
12
Serious AEs
0.0%
Results posted
Jul 2019
Primary outcome: Primary: The Number of Cytokines Showing Statistically Significant Changes From Pre-treatment Levels Will be Recorded. — 0; 0; 0; 0 Cytokines changed from t=0

Study Design & Population

Study type
Interventional
Phase
Early Phase 1
Interventions
Ivermectin (Drug); Placebo (Other)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
University of Georgia
Primary completion
Apr 2018

Outcome Measures

OutcomeResultp-value
PRIMARY
The Number of Cytokines Showing Statistically Significant Changes From Pre-treatment Levels Will be Recorded.
0; 0; 0; 0
PRIMARY
Number of Transcripts in PBMC With Statistically Significant Changes From Pre-treatment Levels.
0; 0; 10; 0
SECONDARY
Complete Blood Counts (CBC)
3.069; 3.341; 2.940; 3.358; 1.753; 1.864 <0.05 sig

Summary

We hypothesize that ivermectin, a drug used to treat parasitic worm infections, interacts with the human innate immune system and that this contributes to its anti-parasitic effects. Participants will donate blood before and after being administered the normal human dose of the drug. We will compare the cell types present in the blood and the chemicals known to influence the human immune system before and after the drug is given, as well as measuring any changes in gene expression in white blood cells 4 and 24hrs after the drug is taken.

Eligibility Criteria

Inclusion Criteria

  • Weight over 110 pounds and under 185 pounds

Exclusion Criteria

  • Pregnancy or nursing mothers.
  • Immunosuppressed individuals.
  • Hypersensitivity to ivermectin, cellulose, starch, magnesium stearate, butylated hydroxyanisole, or citric acid powder (inert ingredients of Stromectol).
  • Recent (last 3 years) travel to West or Central Africa, or any other country where onchocerciasis is present
  • Hepatitis/HIV
  • Currently taking warfarin
  • Lactose intolerance (Lactose present in placebo)
  • Currently taking Steroid medications (inhaled, oral or injection)
  • Currently taking Barbiturates, Benzodiazepines such as Xanax or Klonopin, Valproic acid (Lithium), Calcium channel blockers, Statins (cholesterol medication)
  • Liver or renal dysfunction
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03459794). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search